ArticleInternational journal of general medicine2026
Development and Validation of a Nomogram to Predict Multidrug-Resistant Organism Infection in Severe Pneumonia: A Retrospective Cohort Study.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A practical nomogram for predicting multidrug-resistant organism infection in a tertiary county-level hospital to guide antimicrobial therapy.New microbes and new infections · 2026Article
- Risk Factors and Medical Burden of Multidrug-Resistant Organism Infection in Hospitalized Patients with Pneumonia.Infection and drug resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The purpose of this study was to explore the etiological characteristics of multidrug-resistant bacteria (MDRO) infection in patients with severe pneumonia (SP) and to construct a nomogram model based on their risk factors. Methods: A total of 214 severe pneumonia (SP) patients admitted from November 2022 to January 2024 were retrospectively assigned to the modeling group, and 92 patients admitted from February 2024 to March 2025 formed the validation group. Patients were categorized into MDRO and non-MDRO groups based on multidrug-resistant organism infection status. The distribution of pathogens in the MDRO group was analyzed. Logistic regression was performed to analyze the influencing factors. R software was performed to construct nomogram models. Decision curve analysis(DCA) was performed to evaluate the clinical application value of nomogram models. Results: A total of 93 strains of pathogenic bacteria were isolated from 72 MDRO-infected patients. Gram-negative bacteria showed the highest resistance to piperacillin-tazobactam and piperacillin, while Gram-positive bacteria exhibited a high resistance rate to penicillin.Logistic analysis showed types of pneumonia, chronic obstructive pulmonary disease(COPD), invasive examination,intensive care unit(ICU) admission, antimicrobial drug combination, use of carbapenems, and hypoalbuminemia were risk factors (P<0.05). The modeling group achieved an area under curve(AUC) of 0.910, with the Hosmer-Lemeshow (H-L) test showing χ Conclusion: The types of pneumonia, COPD, invasive examination, ICU admission, combination of antimicrobial drugs, carbapenems use, and hypoalbuminemia are influencing factors for MDRO infection in SP patients. The nomogram constructed based on this can better evaluate the risk of MDRO infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.